Abstract Background/purpose: The incidence of carbapenem-resistant Pseudomonas aeruginosa (CRPA) related healthcare-associated infection (HAI) has increased in recent year worldwide. This study is to investigate the risk factors associated with CRPA infections in a university hospital setting in Taiwan to provide more information for clinician and infection control system. Methods: A retrospective cross-sectional study was conducted from January 1st, 2009 to June 30th, 2014. Patients with P. aeruginosa related HAI were included and divided into the CRPA case group and carbapenem-susceptible Pseudomonas aeruginosa (CSPA) control group. The medical records were reviewed to identify risk factors for CRPA HAI and mortality. Patients with prior use of any anti-pseudomonal carbapenems were included in subgroup analysis. Results: 395 cases of P. aeruginosa infection were enrolled from total of 3263 HAI events; 63 were CRPA and 332 were CSPA. The prevalence of CRPA was 15.9% (63/395). Significant risk factors related to CRPA infection were longer time at risk, prior use of anti-pseudomonal carbapenems, and prior use of aminoglycoside (p < 0.05, 0.01, and 0.05). Furthermore, antipseudomonal carbapenem monotherapy did not significantly increase risk for CRPA infection. Conclusion: The worldwide CRPA prevalence has been on the raise and Taiwan has been also keeping up with the trend. Antimicrobials usage should be monitored carefully, especially with
Introduction
Antimicrobials resistance has been an ever growing concern globally. 1 Many broad-spectrum antibiotics such as Carbapenems have been widely used and followed by the raise of drug resistance in many microorganisms, one of whom is Pseudomonas aeruginosa.
2
Pseudomonas aeruginosa, as one of the major pathogens of healthcare-associated infections (HAI), is associated with substantial higher mortality and morbidity rates compared to other pathogens. 1, 3 Infections caused by P. aeruginosa have always been challenging to healthcare providers due to their intrinsic resistance against a wide variety of antimicrobials.
2. 4 The 2nd-quarter report of Taiwan Nosocomial Infection Surveillance System (TNIS) from the Center for Disease control (CDC) in Taiwan indicated that 7.5%e9.2% of HAI have been caused by P. aeruginosa in 2014.
Carbapenems, a class of broad-spectrum b-lactam antibiotics, are often the last resort against treating nosocomial infections when all else has failed. As a result, resistance to this class of antimicrobials may limit clinical therapeutic choice. According to the annual report of TNIS, carbapenem-resistant P. aeruginosa (CRPA) was responsible for approximately 15 .5% (medical centers) to 18.8% (regional hospitals) of healthcare-associated P. aeruginosa infections during the first half of 2014.
From 2009 to the first half of 2014, in intensive care units (ICU) setting of regional hospitals and medical centers in Taiwan, the overall prevalence of CRPA was between 14% and 20%. Furthermore, if we analyze only the ICUs of Taipei, the prevalence was reported to be even higher, between 15% to 23%. It was no exception for Taipei Medical University hospital (TMUH), a teaching hospital in Taipei. Our rates of CRPA in ICU patients have been on the raise since 2013; the prevalence rate was 10%, and reached 25% for the first half of 2014 and 33.3% during the second half of 2014. As a result, the infection control office of TMUH have been motivated to deal with this healthcare-related epidemic.
This study not only aims to identify the possible risk factors for acquiring healthcare-associated CRPA infection in a university hospital. Moreover, it was conducted with the intention of identifying possible risk factors regarding antibiotics resistance in the effort to guide clinicians in the future to infection control.
Methods

Study population and study design
Taipei Medical university hospital (TMUH) is a private, tertiary care, an 800-bed general teaching hospital in Taiwan. The hospital contains an emergency department with medical and surgical intensive care units.
This retrospective cross-sectional study was conducted at TMUH with a time frame set from January 1st, 2009 to June 30th, 2014. Patients were diagnosed as having P. aeruginosa related HAI 48 h after admission. The definition of HAI is consistent with the definition and criteria for specific types of infections from CDC. 5 Patients with P. aeruginosa related HAI were included in this study and divided into the CRPA case group and CSPA control group. Patients with incomplete medical record were excluded. The primary outcome was to analyze possible risk factors for CRPA infection and the secondary outcome was to compare the 30-day all-cause mortality rate in two groups analyzed by logistic regression. Patients with prior use of any anti-pseudomonal carbapenems were then selected for subgroup analysis (Fig. 1) .
Bacterial isolates and antimicrobial susceptibility testing
Phoenix Automated Microbiology System (Becton Dickinson, Sparks, MD, USA) was used to determine the antimicrobial susceptibility of P. aeruginosa isolates. Antimicrobials susceptibility to anti-pseudomonal agents such as imipenem, meropenem, amikacin, ceftazidime, cefepime, ciprofloxacin, gentamycin, levofloxacin, piperacillin, piperacillin/ tazobactam, were also determined by the MIC results in the department of laboratory in TMUH according to the criteria of the Clinical and Laboratory Standards Institute (CLSI) guidelines. 6, 7 In our study, CRPA defined as MIC of imipenem and/or meropenem !8 mg/mL and remained P. aeruginosa isolates as CSPA.
Data collection
We reviewed patients' charts for data collection, including patients' age, gender, underlying disease, infection site, ward type, room number, hospitalization days, the time at risk, mortality, the prior exposure of invasive procedure during time at risk, prior use of antimicrobials, and the antimicrobials susceptibility test of the culture. The definition of the time at risk is the number of hospitalization days before positive culture of P. aeruginosa.
Invasive procedures such as central catheter (including central venous catheter, permanent catheter, port-A catheter, double lumen catheter, peripherally inserted central catheter and arterial catheter), urinary catheter, chest tube, mechanic ventilation, and extra-corporeal membrane oxygenation (ECMO) were recorded routinely and marked down as prior exposure of invasive procedures as followed during time at risk.
Prior use of antimicrobials was defined as any antimicrobials use within 90 days before the positive P. aeruginosa culture. The antimicrobials were classified as followed: penicillin and derivatives, cephalosporins, carbapenems, fluoroquinolone, aminoglycoside, sulfamethoxazole/ trimethoprim, vancomycin, teicoplanin, fosfomycin, metronidazole, clarithromycin, erythromycin, clindamycin, tigecycline, doxycycline, colistin and anti-fungal agents.
Statistical analysis
All of data were analyzed by Statistical Package for Social Sciences software for Windows version 20 (SPSS, Inc., Chicago, Illinois, USA). The continuous variables of descriptive statistics were tested by Student's t-test while the categorical variables were tested by Chi-square test. A p-value less than 0.05 was considered statistically significant. In the inferential statistics, the odds ratios of all variables were analyzed by logistic regression and a p-value less than 0.05 was considered to be significant.
Results
Study population
A total of 3263 HAI events were enrolled during the study period. Among them, 395 cases (12.1%) were caused by P. aeruginosa and subsequently included to this study. Further analysis showed that 63 (15.9%) were CRPA (case group) and 332 (84.1%) were CSPA (control group).
The average age was 71.2 years old and 62% of them were male. The most common underlying disease was hypertension (52.2%), followed by malignancy (37.0%), diabetes mellitus (29.4%), coronary artery disease (16.7%), stroke (16.7%), and heart failure (10.6%). The statistical breakdown based on infection source was as followed: lower respiratory tract infection (33.4%), urinary tract infection (29.6%), blood stream infection (22.8%) and surgical site infection (7.8%). The average of hospitalization day was 54.2 days while the average time at risk was 27.6 days.
138 (34.9%) events occurred in ICUs, 243 (61.5%) from general wards and most (79.2%) were exposed to some sort of invasive procedure prior to infection confirmation. Furthermore, if we stratify the patients based on departments of admission, internal medicine department had a higher rate of CRPA contraction than in surgical department, both in general ward (37.9% versus 6.4%) and ICU (20.6% versus 11.1%).
Risk factors for CRPA infection
Patients' characteristics and the result of univariate logistic analysis for CRPA and CSPA are illustrated in Table 1 . Figure 1 . Cross-sectional study design and study flow chart. TMUH: Taipei Medical University Hospital; MIC: minimum inhibitory concentration; CSPA: carbapenem-susceptible P. aeruginosa; CRPA: carbapenem-resistance P. aeruginosa. In the CRPA group, the average of hospitalization days was 80 days and time at risk was 47 days, which were 1.6-fold and 2-fold significant longer than the CSPA group (49.3 days and 23.9 days), respectively. There were 36.5% CRPA events and 34.6% CSPA events observed in ICUs. In the univariate logistic analysis of risk factor for CRPA HAI acquisition, the current results showed that older patients were more likely to be infected by CRPA (p Z 0.05). Patients in the CRPA group with underlying diseases such as hypertension, heart failure, coronary artery disease (p < 0.05) were significantly higher than in CSPA group. Moreover, the longer time at risk significantly increased the risk to get CRPA infection (p < 0.001).
The results of multivariate analysis (Table 2) showed time at risk (p < 0.05), prior use of either anti-pseudomonal carbapenems (p < 0.01) or aminoglycoside (p < 0.05) significantly increased CRPA risk, which might have contributed the development of drug-induced antibiotic resistance in P. aeruginosa.
In subgroup analysis, prior use of anti-pseudomonal carbapenems in monotherapy did not significantly increase the risk to get CRPA infections (OR: 4.50, 95% CI: 0.48e42.25) compared to combination therapy by the univariate logistic regression.
Mortality and outcomes
The 30-day all-cause mortality rate in the CRPA group was 30.2% (19 events), while 31.9% (106 events) in the CSPA group. The analysis of the multivariate logistic regression showed that patients with underlying disease of malignancy (adjusted OR: 2.05, 95% CI: 1.15e3.68) and invasive procedure of central line during time at risk (adjusted OR: 1.82, 95% CI: 1.07e3.09) were significantly associated with a higher mortality rate. However, patients infected by CRPA did not have higher mortality rate compared with those patients with CSPA infections (adjusted OR: 0.70, 95% CI: 0.97e1.33) ( Table 3 ).
Discussion
P. aeruginosa, as one of major cause of HAI due to it's minimal nutrition requirements, can be found almost everywhere in the hospital including inanimate objects. 8, 9 This study was a retrospective cross-sectional study. And the study design may decline confounding factors of environmental risks by collecting data from same hospital. In addition, only patients who were confirmed to have HAI caused by P. aeruginosa were included in this study to avoid the bias that might be caused by patients with colonization. Several studies have reported that risk factors associated with CRPA acquisition are the presence of multiple comorbidities, length of hospitalization, receiving invasive procedures and prior use of antibiotics.
10e17 Consistent with many other studies, 11e13,18 there was a positive correlation between the length of hospitalization stays prior to CRPA confirmation and the rate of CRPA contraction. Our study indicated the risk of CRPA infection increasing 1% with each hospitalization day.
In a six-month prospective study in 1997, there were 22.1% of resistant P. aeruginosa isolates found in the medical ICU but only 13.7% in the surgical ICU. 19 The higher rate of CRPA HAI in internal medicine department than in surgical department is observed in our study. The possible explanation might be related to the increased rate of antimicrobials prescription in the internal medicine wards.
Prior antimicrobials use was reported to be associated with the development of drug resistance in the CRPA infection. 20, 21 Either individual susceptibility or the indirect effect of cross-transmission influence to drug-resistance strains were theories acquisition of CRPA. 22 Another subgroup analysis was conducted regarding the prior use of antimicrobials during 90 days before the discovery of positive P. aeruginosa cultures. Compared to other studies that defined prior antibiotic exposure as 14e40 days before confirmed infection, we delineated prior use as 90 days prior.
10e12, 14 After adjusting for covariates, prior use of anti-pseudomonal carbapenems (p < 0.001) and aminoglycoside (p < 0.05) showed a was associated with a significant rise in CRPA infections.
In many previous caseecontrol studies, prior use of antipseudomonal carbapenems such as imipenem and 24e26 Although previous studies show that aminoglycoside use is associated with CRPA both in a population-based ecological study 14 and an individual-level caseecontrol study, 16 there is a lack of evidence for aminoglycoside-induced CRPA. Furthermore, although there was a reported emergence of carbapenem resistance associated with the previous use of fluoroquinolone in a 2014 Taiwan study, 17 our study could not confirm such clams.
Antimicrobial susceptible test in this study has showed that the susceptible rate of P. aeruginosa isolated from CRPA group were still with over toward certain drugs such as amikacin, piperacillin/tazobactam, gentamycin, ciprofloxacin, levofloxacin and piperacillin. The crossresistance pattern in P. aeruginosa between carbapenems and other antimicrobials were similar to other previous study. 14, 15 A prior study indicated monotherapy may play a part in the development of drug resistance in P. aeruginosa, 24, 27 but currently, it still remains inconclusive. Many other researches focused on outcome and safety comparing Carbapenem monotherapy and combination therapy. According to past pharmacokinetic and pharmacodynamic studies, continuous infusion of carbapenem as a monotherapy was performed rigorously in our hospital for years to enhance the therapeutic effects while reducing adverse reactions. Thus, our subgroup analysis aimed to investigate the association between drug resistance and the use of Carbapenems in either monotherapy or combination therapy. The outcome did not reveal any statistical significance due to the lack of power with regards to the insufficient patient count in the combination therapy group.
There was no difference in the mortality rate of patients between the CRPA group and CSPA group, consistent with preceding review articles in Taiwan. 17 There were two studies that revealed several factors related to mortality such as severe sepsis, high-risk source, severity of illness, and capacity of CRPA to form biofilm. 28, 29 In this study, the presence of underlying diseases such as malignancy and prior use of central line were statistical significant risk factors for increasing mortality rate, which indicated that the deaths might be related to malignancy and the use of central lines reflected critical illness. We believe the severity of comorbidity and critical illness are contributory factors to increasing mortality.
We recognize that there are several limitations to our study. Primarily, this was a retrospective observational study, thus there were several variables that weren't able to be controlled at beginning of the study design. The multivariate logistic regression model was therefore used to adjust the baseline of patients. Secondly, the limited number of study patients restricted the matching of the case and control group which might lead to some unforeseen confounding factors of bacteria transmission in the environment. In addition, inadequate sampling might also result in the lack of power for some critical factors. Furthermore, we had no control over patients' prior exposure to antimicrobials as well at the adherence and compliance to such medications. Besides, the time at risk could possibly be underestimated if patients were transferred from other hospital. Lastly, this study did not register the genotype or mechanism of CRPA isolates, which was important information for back-tracing the source of infection, and this might lead to another study.
In conclusion, the current results have revealed that three specific risk factors for CRPA infections among HAI patients in TMUH as followed: the days of hospitalization before positive culture, a prior use of anti-pseudomonal carbapenems, and a prior use of aminoglycoside. Antipseudomonal carbapenem monotherapy did not significantly increase the risk to get CRPA infection. Contrary to most earlier studies, mortality was not linked with carbapenem resistance in our study. Further study on larger populations with carbapenem use would be needed to confirm the association between monotherapy and increasing risk of CRPA infection, and even to possibly conduct a bacterial genomic study for epidemiology to further improve our healthcare system.
